Found 28 clinical trials
Randomized Double-blind Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility
- 0 views
- 22 Jan, 2021
Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
Pharmaceutical Co., Ltd.) for lymphoma and anemia patients are less clinical studies.Therefore, a prospective, open-label, multicenter clinical study of recombinant human erythropoietin in the treatment of
- 0 views
- 21 Aug, 2021
- 1 location
Paricalcitol Improves Anemia of Inflammation (PIERAID)
expression. The paricalcitol for the secondary hyperparathyroidism control may improve AI decreasing erythropoietin stimulating agents (ESAs) dosage.
- 30 views
- 04 Oct, 2022
- 1 location
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)
- 2 views
- 07 Oct, 2022
- 1 location
Mechanisms of EPO-induced Hypertension (EPIC)
The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The
- 0 views
- 23 Mar, 2022
- 1 location
Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome (SMD-transfu)
transformation. Anemia is the most common manifestation of bone marrow failure in MDS. After failure with first-line treatment by Erythropoietin, patients survive in average 5 years under long term blood
- 0 views
- 18 Apr, 2022
- 17 locations
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
The purpose of our study is to determine the safety and efficacy of the combination of erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with neurological
- 0 views
- 26 Jan, 2021
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
- 0 views
- 25 Mar, 2022
- 1 location
Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients (FeVitC)
The administration of ascorbic acid seemed to increase the iron available for erythropoiesis, thus improving the anemia response to the treatment. The investigators therefore aimed to evaluate the effects of intravenous ascorbic acid administration in hemodialysed patients with iron overload.
- 0 views
- 28 Feb, 2022
- 1 location
Iron Supplementation and Neurodevelopmental Outcome in ELGANs
This study explores the relationship between iron deficiency and neurological outcome of extremely premature infants. Premature birth occurs during a critical period of brain development and maturation, and before adequate transfer of iron across the placenta. Nutrition has a significant impact on ultimate outcome of survivors of prematurity. One of …
- 0 views
- 13 Aug, 2021
- 1 location